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Objective: Off-pump coronary artery bypass grafting reduces postoperative morbidity and uses fewer resources
than conventional surgical intervention with cardiopulmonary bypass. However, only 15% to 20% of coronary
artery bypass grafting operations use off-pump coronary artery bypass. One reason for not using off-pump cor-
onary artery bypass might be the surgeon’s concern about the long-term patency of grafts performed with this
technique. Therefore our objective was to compare long-term outcomes in patients randomized to off-pump cor-
onary artery bypass or coronary artery bypass grafting with cardiopulmonary bypass.
Methods: Participants in 2 randomized trials comparing off-pump coronary artery bypass and coronary artery by-
pass grafting with cardiopulmonary bypass were followed up for 6 to 8 years after surgical intervention to assess
graft patency, major adverse cardiac-related events, and health-related quality of life. Patency was assessed by using
multidetector computed tomographic coronary angiographic analysis with a 16-slice scanner. Two blinded ob-
servers classified proximal, body, and distal segments of each graft as occluded or not. Major adverse cardiac-re-
lated events and health-related quality of life were obtained from questionnaires given to participants and family
practitioners.
Results: Patency was studied in 199 and health-related quality of life was studied in 299 of 349 survivors. There
was no evidence of attrition bias. The likelihood of graft occlusion was no different between off-pump coronary
artery bypass (10.6%) and coronary artery bypass grafting with cardiopulmonary bypass (11.0%) groups (odds
ratio, 1.00; 95% confidence interval, 0.55–1.81; P> .99). Graft occlusion was more likely at the distal than the
proximal anastomosis (odds ratio, 1.11; 95% confidence interval, 1.02–1.20). There were also no differences be-
tween the off-pump coronary artery bypass and coronary artery bypass grafting with cardiopulmonary bypass
groups in the hazard of death (hazard ratio, 1.24; 95% confidence interval, 0.72–2.15) or major adverse car-
diac-related events or death (hazard ratio, 0.84; 95% confidence interval, 0.58–1.24), or mean health-related qual-
ity of life across a range of domains and instruments.
Conclusions: Long-term health outcomes with off-pump coronary artery bypass are similar to those with coro-
nary artery bypass grafting with cardiopulmonary bypass when both operations are performed by experienced
surgeons.
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doi:10.1016/j.jtcvs.2008.09.046The Journal of Thoracic and CThere is high-quality evidence that off-pump coronary artery
bypass (OPCAB) grafting reduces the risk of postoperative
morbidity and1,2 intensive care unit and hospital stays1 and
uses fewer resources3-5 than conventional surgery with car-
diopulmonary bypass (CPB). However, only a minority of
coronary artery bypass grafting (CABG) operations world-
wide, about 15% to 20%, are carried out with the OPCAB
technique.6,7
Surgeons might be reluctant to take up OPCAB because
of concerns that the technique requires distal anastomoses
to be performed on the beating heart, potentially compromis-
ing long-term patency. The literature on graft patency from
randomized controlled trials (RCTs) of OPCAB versus
CABG–CPB is inconsistent, and authors have reported find-
ings for only relatively short durations of follow-up.1,8
We performed 2 of the earliest RCTs of OPCAB versus
CABG–CPB: the Beating Heart Against Cardioplegic Arrest
Study (BHACAS) 1 and 2. We have previously reported clin-
ical and health-related quality of life (HRQoL) findings atardiovascular Surgery c Volume 137, Number 2 295
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DAbbreviations and Acronyms
BHACAS ¼ Beating Heart Against Cardioplegic
Arrest Study
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
CPB ¼ cardiopulmonary bypass
HRQoL ¼ health-related quality of life
ITA ¼ internal thoracic artery
MACE ¼ major adverse cardiac-related event
MDCTA ¼ multidetector computed tomography
coronary angiography
OPCAB ¼ off-pump coronary artery bypass
RCT ¼ randomized controlled trial
SD ¼ standard deviation
SV ¼ saphenous vein
2 to 3 years.9,10 Here our objective is to report long-term fol-
low-up (6–8 years) in survivors for clinical outcomes,
HRQoL, and graft patency by using multidetector computed
tomographic coronary angiographic (MDCTA) analysis.11
MATERIALS AND METHODS
BHACAS Trials
Details of the trials have been reported elsewhere.9,12 Patients were re-
cruited from March 1997 to August 1998 (BHACAS 1) and from September
1998 to November 1999 (BHACAS 2). Participants were randomly as-
signed to the OPCAB or CABG–CPB groups. Ethical approval to carry
out the studies was obtained from the local research ethics committee (ref-
erence E3791).
MDCTA Protocol
MDCTA is a noninvasive method of imaging with high sensitivity and
specificity compared with conventional coronary angiography.11 Exclusion
criteria for MDCTA were as follows: inability to lie flat, heart rate greater
than 100 beats/min, allergy to contrast medium, impaired renal function (se-
rum creatinine,>130 mmol/L), pregnancy, or inability to provide informed
consent. Patients with a heart rate of greater than 65 beats/min and no con-
traindication to b-blockade were given 50 to 100 mg of metoprolol 60 to 90
minutes before MDCTA.
A 16-slice scanner (Somatom Sensation 16; Siemens, Berlin, Germany)
was used. The scanning protocol consisted of 3 steps. First, an initial short
tomogram (50 mA; 80 kV; collimation, 1 mm) was performed to set upper
and lower scan levels and reconstruction margins for the heart. Second,
a test bolus scan was administered to determine the circulation time of the
contrast medium. The start of the contrast-enhanced coronary scan was
adapted by adding 3 seconds to the calculated circulation time to allow
for homogeneous mixing of the contrast medium throughout the coronary
arterial tree. Third, a contrast MDCTA spiral scan (550 mAs, 120 kV, 16
3 0.75–mm slice width collimation, 0.42-second rotation time, and 2.8
mm feed per rotation) was performed with contrast medium (125 mL of Io-
meron 400 at 4 mL/s, Braceo Group, San Donato Milanese, Italy) infused at
the start time, as described above. The scan was in a caudocranial direction,
with the upper margin at the level of the clavicles to include internal thoracic
artery (ITA) grafts and the lower margin just below the base of the heart.
Dedicated spiral algorithms provided 105- to 250-ms temporal resolution
from retrospective electrocardiogram-triggered phase reconstruction,
depending on heart rate and the vessel segment under consideration. The296 The Journal of Thoracic and Cardiovascular Surcoronary scan has serial phase image reconstruction performed with retro-
spective gating between 60% and 40% absolute reverse (1-mm slice
width, B30f medium smooth kernel).
Assessment of MDCTA Images
Images were interpreted on computer workstations (Wizard/Leonardo,
Siemens) by 2 independent observers blinded to randomized allocation.
Analysis of grafts was carried out from thin maximum-intensity projection
slices and 3-dimensional volume images. Scans were reported by using an
established system.13
Each graft was classified by conduit type (pedicle ITA or gastroepiploic
artery [1 graft only], free ITA, radial artery, and saphenous vein [SV]) and
assessed in 3 segments: the proximal anastomosis, the body of the graft, and
the distal anastomosis. Each segment was classified as patent (flow visible),
occluded, or not analyzable (eg, because the segment was obscured by
a metal ligature clip or because the image quality was poor).
Follow-up to Assess Outcomes
Participants were followed up through the National Health Service Stra-
tegic Tracing Service and by annual questionnaire for major adverse car-
diac-related events (MACEs); we also sent annual questionnaires to
family practitioners.14 MACEs were defined as follows: (1) recurrent angina
(hospital visit for angina reported by patient or hospital admission for angina
reported by general practitioner); (2) myocardial infarction (hospital visit for
myocardial infarction reported by patient or hospital admission for myocar-
dial infarction reported by general practitioner); and (3) repeat revasculari-
zation (repeat operation or angioplasty since the index operation reported by
patient or general practitioner). Reported admissions to the Bristol Heart In-
stitute were all verified.
Survivors were sent 4 HRQoL questionnaires10 (ie, the Seattle Angina
Questionnaire,15 the Coronary Revascularisation Outcome Questionnaire,16
the Short-Form Health Survey 36 version 2,17,18 and the EuroQol19) with
their annual surveillance questionnaire. If there was no response to the first
mailing, after a month, a second questionnaire was sent. If neither elicited
a response, the patient was telephoned to find out whether there was a par-
ticular reason, such as ill health, preventing completion of forms. Patients
who indicated that they would like to undergo MDCTA but did not return
their questionnaires were asked to complete them when attending for
MDCTA. Patients who were not able to complete the questionnaires them-
selves (eg, because of poor sight) were invited to complete them by tele-
phone or face-to-face.
Statistical Analyses
Patency. Agreement between initial assessments of graft patency by the
2 observers was described by using the k statistic. When grafts were as-
sessed by observer 1 but classified as not analyzable by observer 2, the as-
sessment of observer 1 was used and vice versa. Disagreements between
observers were reconciled, if necessary, by a third observer.
Patency was analyzed by means of multivariable logistic regression (oc-
cluded or not), with segments as individual observations. Robust standard
errors were estimated to take account of nesting of grafts within patients.
Segments that could not be analyzed by either observer were excluded. Ran-
domized allocation, trial (BHACAS 1 or 2), segment, conduit, and graft ter-
ritory were included as covariates. Two interactions with operation type
were also investigated: (1) allocation by trial to check the validity of pooling
data across trials and (2) allocation by segment to test the prior hypothesis
that distal anastomoses are more likely to occlude with OPCAB than with
CABG–CPB.
All-cause mortality and MACEs. Cox regression analyses were
carried out for 3 outcomes: (1) all-cause mortality; (2) all-cause mortality or
MACEs; and (3) MACEs only. All participants were included in the analy-
sis of all-cause mortality, censoring surviving participants at the last known
date of follow-up. For survival free from MACEs or death, participants weregery c February 2009
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Dcensored at the last known date of follow-up if alive and free from MACEs.
For the analysis of MACEs only, participants were censored at death if free
from a MACE at this time. Models included type of operation and trial (ie,
BHACAS 1 or 2). The interaction of allocation by trial was tested. Validity
of the proportional hazards assumption was checked in all models.
HRQoL. HRQoL questionnaires were scored as previously reported.10
For all dimensions, higher scores represent better HRQoL. Linear regression
models fitted type of operation and trial. The interaction of operation allo-
cation by trial was tested. Confidence intervals (CIs) for differences between
the CABG–CPB and OPCAB groups were estimated by means of bootstrap-
ping because some distributions of scores were skewed. Analyses of all out-
comes were by intention to treat.
Sample size justification. Original sample sizes were based on
length of stay.9 In the protocol for this follow-up, we stated that patency
would be analyzed for grafts and not patients, gaining additional power
from multiple grafts per patient (approximately 2.5 grafts per patient). We
expected to analyze data for 320 patients, providing 800 grafts for study. As-
suming a design effect of 1.3 (intraclass correlation, 0.2), the study would
have an effective sample size of about 610 ‘‘independent’’ observations.
The graft occlusion rate was expected to vary by conduit: in patients un-
dergoing CABG–CPB, we expected approximately 10% of arterial and ap-
proximately 40% of SV grafts to be occluded. (Although the occlusion rate
was expected to vary by conduit type, no interaction of conduit type and op-
eration type was hypothesized.) Among participants who contributed to the
previous follow-up,10 47% (388/834) of grafts were arterial conduits.
Therefore the overall graft ‘‘failure’’ rate in the CABG–CPB group was es-
timated to be approximately 26%: (10%347%)þ(40%353%).
Based on the above assumptions, we calculated that the study would
have 80% power to detect an absolute difference of 11% (ie, 26% vs
37% or a relative risk of 1.4) in the risk of graft occlusion (a¼ .05, 2-tailed)
or to exclude the possibility of differences smaller than 8% (a ¼ .05, 2-
tailed). The pooled data had 90% power to detect a small-to-moderate stan-
dardized difference (0.43) in HRQoL (a ¼ .01, 2-tailed), assuming about
90% of survivors (350 3 0.90z 320) responded.
RESULTS
Deaths, numbers and reasons for loss to follow-up, and num-
bers contributing to analyses are shown in Figure 1. Fifty-two
(13.0%) of 401 randomized participants had died, 28 in the
OPCAB group (14%) and 24 in the CABG–CPB group
(12%); of the remaining 349, 299 (86%) completed HRQoL
questionnaires, and 199 (57%) had MDCTA scans.
Table 1 shows the baseline characteristics of all survivors,
those who attended for MDCTA, and those who completed
HRQoL questionnaires. Survivors had similar characteris-
tics at baseline to the entire randomized cohort9; only the
proportions with unstable angina and Parsonnet scores of
greater than 10 appeared to be lower among survivors,
equally for both the CABG–CPB and OPCAB groups. Com-
pared with all survivors, those who had MDCTA scans
tended to be slightly younger and were more likely to be
male but otherwise had similar characteristics. Baseline
characteristics of participants who completed HRQoL ques-
tionnaires were similar to those for all survivors and similar
for the CABG–CPB and OPCAB groups.
Graft Patency
A total of 505 grafts were studied in 199 participants be-
tween January 31, 2005, and August 3, 2006. At least 1 graftThe Journal of Thoracic and Cwas analyzable in each participant, but both observers could
not analyze 13 (2.6%) grafts, and one or the other observer
could not analyze another 24 (4.8%) grafts. Mean durations
of follow-up from the operation to MDCTA were 85.1
months (standard deviation [SD], 4.8) and 85.8 months
(SD, 4.7) for the CABG–CPB and OPCAB groups, respec-
tively. Conduits and coronary territories grafted were similar
in the 2 groups (Table 2).
There was moderate agreement between initial assess-
ments of the 2 observers (k ¼ 0.62 for 505 grafts, analyzing
grafts classified as not analyzable in a separate category; k¼
0.71 for 468 grafts classified by both observers as occluded
or not). Overall, 53 (10.8%) of 492 grafts were classified as
occluded after disagreements were reconciled. Percentages
of grafts classified as occluded were similar in the CABG–
CPB and OPCAB groups, both overall (27/255 [10.6%]
and 26/237 [11.0%], respectively; Table 3) and for arterial
and SV grafts separately (arterial grafts, 13/126 [10.3%]
vs 8/116 [6.9%]; SV grafts, 14/129 [10.9%] vs 18/121
[14.9%], respectively). SV grafts were more likely to be
occluded (32/250 [12.8%]) than arterial grafts (21/242
[8.7%]) but not to the extent expected at the outset.
The logistic regression analysis of graft occlusion showed
no evidence that grafts were more likely to be occluded in
OPCAB than in CABG–CPB participants (odds ratio, 1.00;
95% CI, 0.55–1.81; P> .99; model details in are shown in
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FIGURE 1. Flow diagram showing the numbers of participants random-
ized in the Beating Heart Against Cardioplegic Arrest Studies surviving
to this follow-up, with data contributing to analyses of different outcomes
(and reasons for data not being available). MACE, Major adverse cardiac
event; HRQoL, health-related quality of life; MDCTA, multidetector com-
puted tomography coronary angiography.ardiovascular Surgery c Volume 137, Number 2 297
Acquired Cardiovascular Disease Angelini et al
A
C
DTABLE 1. Baseline demographic and clinical characteristics of CABG–CPB and OPCAB survivors
All survivors Patients who had MDCTA Patients returning HRQoL questionnaires
CABG–CPB
(n ¼ 177)
OPCAB
(n ¼ 172)
CABG–CPB
(n ¼ 101)
OPCAB
(n ¼ 98)
CABG–CPB
(n ¼ 149)
OPCAB
(n ¼ 150)
Variable No. % No. % No. % No. % No. % No. %
BHACAS 2 89 50.3 88 51.2 52 51.5 48 49.0 71 47.7 77 51.3
Male sex 147 83.1 143 83.1 89 88.1 87 88.8 129 86.6 127 84.7
Age (y)* 60.5  8.6 62.0  8.7 59.1  8.3 61.0  8.3 60.9  8.5 62.1  8.2
Diabetes 41 23.2 42 24.4 22 21.8 22 22.5 34 22.8 37 24.7
Previous myocardial infarction
>1 mo 61 34.5 65 37.8 40 39.6 34 34.7 52 34.9 56 37.3
<1 mo 11 6.2 14 8.1 5 5.0 5 5.1 9 6.0 12 8.0
Hypertension 87 49.2 102 59.3 51 50.5 62 63.3 76 51.0y 94 62.7y
Hypercholesterolemia 126 71.2 134 77.9 72 71.3 77 78.6 107 71.8 116 77.3
Smoking history
Current 20 11.3 17 9.9 10 9.9 9 9.2 13 8.7 11 7.3
Exsmoker 106 59.9 108 62.8 56 55.5 64 65.3 90 60.4 96 64.0
Nonsmoker 51 28.8 47 27.3 35 34.7 25 25.5 46 30.9 43 28.8
Unstable angina 62 35.0 65 37.8 33 32.7 36 36.7 46 30.9 57 38.0
Angina class (CCS)
I 22 12.4 15 8.7 14 13.9 6 6.1 21 14.1 12 8.0
II 62 35.0 60 34.9 32 31.7 34 34.7 58 38.9 53 35.3
III 54 30.5 54 31.4 32 31.7 32 32.7 43 28.9 47 31.3
IV 39 22.0 43 25.0 23 22.8 26 26.5 27 18.1 38 25.3
Ejection fraction<50% 41 23.2 37 21.5 25 24.8 16 16.3 35 23.5 32 21.3
Parsonnet score>10 20 11.3 28 16.3 9 8.9 10 10.2 18 12.1 23 15.3
No. of distal anastomoses
1 17 9.6 16 9.3 8 7.9 10 10.2 13 8.7 14 9.3
2 60 33.9 74 43.0 36 35.6 44 44.9 53 35.6 63 42.0
3 76 42.9 65 37.8 44 43.6 33 33.7 62 41.6 56 37.3
4 24 13.6 17 9.9 13 12.9 11 11.2 21 14.1 17 11.3
MDCTA, Multidetector computed tomography coronary angiography; HRQoL, health-related quality of life; CABG–CPB, coronary artery bypass grafting with cardiopulmonary
bypass; OPCAB, off-pump coronary artery bypass; BHACAS, Beating Heart Against Cardioplegic Arrest Study;CCS, Canadian Cardiovascular Society. *Reported as the mean and
standard deviation. yThe difference between the coronary artery bypass grafting with cardiopulmonary bypass and off-pump coronary artery bypass groups was statistically sig-
nificant (P ¼ .04). No other differences for all survivors, patients who had multidetector computed tomographic coronary angiography, or patients who returned health-related
quality of life questionnaires were significant.Table E1). Grafts carried out in BHACAS 2 were less likely
to be occluded (odds ratio, 0.49; 95% CI, 0.27–0.89; P ¼
.02). Graft occlusion was more likely at the distal than the
proximal anastomosis (odds ratio, 1.11; 95% CI, 1.02–
1.20; P ¼ .02); the graft body was no more likely to be oc-
cluded than the proximal anastomosis (odds ratio, 1.02;95% CI, 0.92–1.14; P ¼ .69). The interaction of operation
allocation by trial was not significant (P¼ .59) but suggested
occlusion was more likely with OPCAB compared with
CABG–CPB in BHACAS 1 and vice versa in BHACAS 2
(see Table E2 and Figure E1). The interaction of operation
type and graft segment reached statistical significanceTABLE 2. Distribution of 505 grafts by conduit, coronary territory, and operation type in CABG–CPB andOPCAB 199 patients who hadMDCTA
scans
CABG–CPB OPCAB
Coronary territory Coronary territory
Conduit Anterior Lateral Inferior Anterior Lateral Inferior
Pedicle internal thoracic artery 103 (39.0%) 10 (3.8%) 7 (2.7%) 89 (36.9%) 4 (1.7%) 9 (3.7%)
Free internal thoracic artery 0 (0.0%) 3 (1.1%) 0 (0.0%) 4 (1.7%) 0 (0.0%) 0 (0.0%)
Radial artery 1 (0.4%) 3 (1.1%) 6 (2.3%) 2 (0.8%) 5 (2.1%) 6 (2.5%)
Saphenous vein 27 (10.2%) 50 (18.9%) 54 (20.5%) 39 (16.2%) 32 (13.3%) 51 (21.2%)
Total 131 (49.6%) 66 (25.0%) 67 (25.4%) 134 (55.6%) 41 (17.0%) 66 (27.4%)
Coronary artery bypass grafting with cardiopulmonary bypass¼ 264 (264/101¼ 2.61 grafts per patient); off-pump coronary artery bypass¼ 241 (241/98¼ 2.46 grafts per patient).
Percentages are expressed with respect to denominators of 264 and 241 grafts for coronary artery bypass grafting with cardiopulmonary bypass and off-pump coronary artery by-
pass, respectively. MDCTA, Multidetector computed tomography coronary angiography; CABG–CPB, coronary artery bypass grafting with cardiopulmonary bypass; OPCAB, off-
pump coronary artery bypass.
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D(P ¼ .04) but was not included in the final model because it
did not support the prior hypothesis that distal anastomoses
performed with OPCAB were more likely to be occluded;
odds ratios for OPCAB versus CABG–CPB were 1.08,
1.05, and 0.88 for proximal, body, and distal segments,
respectively (see Table E3 and Figure E2).
Survival and MACEs
Mean durations of follow-up for survival were 75.5 (SD,
20.6) and 76.7 (SD, 19.3) months for OPCAB and CABG–
CPB participants; there were 23 and 29 deaths in each
group, respectively. Cox regression showed no difference
in survival between the 2 groups (hazard ratio, 1.24;
95% CI, 0.72–2.15; P ¼ .44). There was no effect of trial
(P ¼ .51) or the interaction of operation allocation by trial
(P ¼ .36).
TABLE 3. Classification of patency* by type of conduit in 492 grafts in
101 patients undergoing CABG–CPB and 98 patients undergoing
OPCAB
CABG–CPB OPCAB
Conduit
Total
analyzedy
Occluded,
n (%)
Total
analyzedy
Occluded,
n (%)
Pedicle internal thoracic
artery
114 12 (10.5) 101 6 (5.9)
Free internal thoracic
artery
3 0 (0.0) 4 0 (0.0)
Radial artery 9 1 (11.1) 11 2 (18.2)
Saphenous vein 129 14 (10.9) 121 18 (14.9)
Total 255 27 (10.6) 237 26 (11.0)
CABG–CPB, Coronary artery bypass grafting with cardiopulmonary bypass; OPCAB,
off-pump coronary artery bypass. *Grafts were classified as occluded if any segment
was occluded. yIn addition, 9 grafts in patients undergoing coronary artery bypass
grafting with cardiopulmonary bypass and 4 grafts in patients undergoing off-pump
coronary artery bypass could not be analyzed; 7 (6 and 1 in the coronary artery bypass
grafting with cardiopulmonary bypass/off-pump coronary artery bypass groups, re-
spectively) were pedicle internal thoracic artery grafts, 3 were radial artery (1 and 2,
respectively) grafts, and 3 were saphenous vein (2 and 1, respectively) grafts.MACEs that occurred in the 2 groups are shown in Table
4. There were 49 and 39 MACEs in the CABG–CPB and
OPCAB groups and a further 7 and 10 deaths as first events
in each group, respectively (105 participants with1 event).
There are no apparent differences in the number or nature of
first-reported MACEs between the CABG–CPB and OP-
CAB groups.
Mean duration of follow-up in analyses of survival free
from MACEs or death was 62.7 (SD, 29.4) and 64.8 (SD,
28.9) months for the CABG–CPB and OPCAB participants,
respectively. Cox regression showed no difference between
the 2 groups (hazard ratio, 0.84; 95% CI, 0.58–1.24; P ¼
.39; Figure 2). There were no effects of trial (P ¼ .73) or
the interaction of operation allocation by trial (P¼ .31). Sur-
vival free from MACEs or death at 5 years was estimated to
be 78.7% (72.2%–83.8%) and 81.8% (75.6%–86.6%), re-
spectively, in the CABG–CPB and OPCAB groups. Simi-
larly, there was no difference in survival free from MACEs
only between the 2 groups (hazard ratio, 0.77; 95% CI,
0.51–1.18; P ¼ .24), with no effects of trial (P ¼ .15) or
the interaction of operation allocation by trial (P ¼ .21).
HRQoL
Mean durations of follow-up among respondents to the
HRQoL questionnaires were 83.6 (SD, 4.9) and 83.1 (SD,
5.7) months for the CABG–CPB and OPCAB groups,
respectively. Table 5 shows the mean scores for different
domains of HRQoL for the 4 instruments by operation
type and differences between the group means. None of
the differences were statistically significant.
DISCUSSION
Main Findings
The key findings from the long-term follow-up of partic-
ipants in the BHACAS 1 and 2 trials are that there were no
differences between the CABG–CPB and OPCAB groups inTABLE 4. First major adverse cardiac-related event experienced and deaths by allocation and time period
CABG–CPB (n ¼ 201) OPCAB (n ¼ 200)
Event 1 y >1 and 4 y >4 y 1 y >1 and 4 y >4 y
Angina* 16 (8.0%) 14 (7.0%) 8 (4.0%) 15 (7.5%) 10 (5.0%) 3 (1.5%)
Myocardial infarction 3 (1.5%) 2 (1.0%) 3 (1.5%) 2 (1.0%) 2 (1.0%) 4 (2.0%)
Revascularizationy 0 (0.0%) 1 (0.5%) 2 (1.0%) 2 (1.0%) 0 (0.0%) 1 (0.5%)
Death (as first event) 0 (0.0%) 0 (0.0%) 7 (3.5%) 0 (0.0%) 1 (0.5%) 9 (4.5%)
Death (not as first event)z 3 (1.5%) 10 (5.0%) 3 (1.5%) 2 (1.0%) 6 (3.0%) 11 (5.5%)
Any deathx 3 (1.5%) 10 (5.0%) 10 (5.0%) 2 (1.0%) 7 (3.5%) 20 (10.0%)
Percentages are expressed with respect to denominators of 201 and 200 participants who had coronary artery bypass grafting with cardiopulmonary bypass and off-pump coronary
artery bypass, respectively. Note that percentages for the last 2 rows are distinct from the first 4 rows. CABG–CPB, Coronary artery bypass grafting with cardiopulmonary bypass;
OPCAB, off-pump coronary artery bypass. *Eight patients who reported angina subsequently had a myocardial infarction, of whom 3 also reported revascularization (all were in the
coronary artery bypass grafting with cardiopulmonary bypass group; the dates of myocardial infarction and revascularization were the same for 2 patients, and the date of myo-
cardial infarction preceded revascularization for the third patient). yAll 6 patients who underwent revascularization as first events had percutaneous coronary intervention. A further
9 patients are known to have had revascularization after recurrence of angina or myocardial infarction; 7 had percutaneous coronary intervention, and 2 had repeat operations.
zNumbers in this row represent deaths in participants with up-to-date annual surveillance at the time of death (ie, deaths in patients included in the analysis of survival free
from major adverse cardiac event events but that were not included as events because they were preceded by a major adverse cardiac event). xNumbers in this row represent
all deaths.
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Dgraft patency, survival and survival free from MACEs, and
HRQoL 6 to 8 years after surgical intervention.
Strengths and Limitations
Randomized allocation, which minimizes selection bias,
is an important strength of the BHACAS trials which are
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FIGURE 2. Kaplan-Meier graph showing cardiac event–free survival, in-
cluding death. CABG–CPB, Coronary artery bypass grafting with cardio-
pulmonary bypass; OPCAB, off-pump coronary artery bypass.reported here in compliance with the CONSORT statement
(www.consort-statement.org). A further strength is the high
proportion of screened patients who were recruited (almost
50%),9 enhancing the applicability of the findings in our
center.
Attrition during the 6 to 8 years of follow-up is the
main limitation, but this does not appear to have intro-
duced bias (ie, there was no selective attrition by group).
Attrition varied by outcome. Despite its relative noninva-
siveness compared with conventional angiographic analy-
sis, only 57% of survivors underwent MDCTA. The main
reason for not undergoing MDCTA was because some
participants declined to be reinvestigated. However, there
was no difference in the percentages of participants
undergoing MDCTA or differences in their baseline
characteristics by surgical group. There was less attrition
with HRQoL. In survival analyses all participants contrib-
uted up to the last known follow-up. The fact that attrition
bias was not observed for other outcomes suggests that
informative censoring is unlikely to have affected these
analyses.
Because patency data were obtained for only 492 grafts
(effective sample size, 378), analyses of graft patency had
80% power to detect a relative risk of occlusion of about
2.0 (ie, 11% for the CABG–CPB group vs 22% for the
OPCAB group) compared with 1.4 as proposed at the outsetTABLE 5. Mean scores and differences between the CABG-CPB and OPCAB groups for the Short-Form Health Survey 36 (SF-36), the Coronary
Revascularisation Outcome Questionnaire (CROQ), the Seattle Angina Questionnaire (SAQ), and EuroQol
CABG–CPB OPCAB OPCAB vs CABG–CPB
No. Mean SD No. Mean SD Difference 95% CI P value
SF-36*
PCS* 130 53.4 9.5 138 53.0 8.4 0.37 2.56 to 1.82 .74
MCS* 130 52.4 9.9 138 51.0 7.6 1.39 3.45 to 0.66 .18
CROQ
Core total* 148 49.6 7.5 145 50.3 7.0 0.79 0.87 to 2.51 .35
Symptomsy 146 85.2 20.0 144 86.6 18.6 1.43 2.81 to 5.68 .51
Physical functioningy 146 74.2 29.1 144 77.0 27.0 2.88 3.55 to 9.32 .38
Cognitive functioningy 147 78.8 23.3 146 81.8 22.7 3.06 2.08 to 8.19 .24
Psychosocial functioningy 148 82.8 20.9 146 85.3 19.0 2.55 1.83 to 6.94 .25
Satisfactiony 147 82.7 21.7 145 84.6 18.8 1.84 2.84 to 6.52 .44
Adverse effectsy 146 93.5 11.0 140 95.3 8.5 1.86 0.50 to 4.23 .12
SAQ
Physical functiony 136 72.4 25.8 130 75.0 24.9 2.59 3.53 to 8.70 .41
Angina frequencyy 139 88.8 22.5 138 89.6 19.7 0.76 4.14 to 5.65 .76
Angina stabilityyz 40 45.6 23.9 43 46.5 24.1 0.93 9.60 to 11.5 .86
Treatment satisfactiony 106 89.2 20.2 110 91.5 16.3 2.33 2.59 to 7.25 .35
Quality of lifey 117 74.0 25.7 118 77.0 23.4 3.04 3.38 to 9.45 .35
EuroQol
Utilityx 135 0.80 0.25 136 0.82 0.24 0.01 0.05 to 0.07 .64
Health statusx 136 73.0 18.6 140 75.8 17.1 2.77 1.41 to 6.96 .19
Higher scores indicate better quality of life. Numbers vary because some respondents did not complete all items. CABG–CPB, Coronary artery bypass grafting with cardiopulmo-
nary bypass; OPCAB, off-pump coronary artery bypass. *Scored on a scale with a mean of 50 and SD of 10. SF-36 physical (PCS) and mental (MCS) component summary scores
are also normalized: 50 represents the mean for the reference (ie, ‘‘normal’’) population. yScored on a scale from 0 to 100. zNinety-four participants in the coronary artery bypass
grafting with cardiopulmonary bypass group and 92 in the off-pump coronary artery bypass group reported no angina; these responses do not equate to a score. xScored on a scale
from 0 to 1.
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D(ie, 26% for the CABG–CPB group vs 37% for the OPCAB
group). Note that this post-hoc calculation is based on the
observed lower frequency of graft occlusion (11%), as
well as the smaller sample size available.
Finally, it is important to remember that the BHACAS tri-
als were carried out in a single center by a single academic
surgical team. This surgical team has documented innova-
tions in OPCAB technique, their performance and that of
residents learning OPCAB, and other aspects of their expe-
rience with OPCAB over more than a decade. Therefore cau-
tion should be exercised in generalizing these findings to
other surgeons and centers.
Findings in the Context of Other Literature
We did not synthesize our findings with those of other
RCTs that have reported graft patency because the follow-
up reported here was much longer and patency was assessed
by means of MDCTA and not conventional angiographic
analysis. Angiographic findings up to 1 year from previous
RCTs have been pooled in a meta-analysis without statistical
evidence of heterogeneity.8 However, this analysis took no
account of varying duration of follow-up (from discharge
to 1 year), varying attrition, or the lack of independence of
grafts within patients. If occluded grafts tend to be in the
same patients, as suggested by our data and by other studies,
this latter failing could seriously undermine statistical infer-
ences.
Three trials have reported 1-year patency findings that
were subject to attrition, ranging from 22% to 36%, and
none found a significant difference.4,5,20 Two trials com-
pared the proportion of grafts that were patent but took no
account of nesting of grafts within patients; both found a dif-
ference in patency of 2% favoring the CABG–CPB
group.4,5 The third trial correctly compared the proportion
of patients with none, 1, or at least 2 occluded grafts, observ-
ing differences of 2% to 6% favoring the OPCAB group.20
However, only about 50% of patients had all grafts patent at
1 year compared with 75% after 6 to 8 years in this study.
One additional small trial reported that grafts performed dur-
ing OPCAB were more likely to be occluded at 3 months
(88% vs 98%).21 This trial was not powered to find a differ-
ence in graft patency and took no account of nesting of grafts
within patients.
Given the time since surgical intervention, we observed
few occluded grafts. The low rate of occlusion of SV grafts
was particularly surprising. This might, in part, be due to
early routine administration of aspirin (300 mg per rectum)
during the first 6 hours and lifetime use of statins after sur-
gical intervention. Our patency findings cannot be directly
compared with previous findings, not least because of poten-
tial differences between conventional angiographic analysis
and MDCTA. Although MDCTA has high sensitivity and
specificity in detecting graft patency,11 we cannot rule out
the presence of stenoses in patent SV grafts.The Journal of Thoracic andMetal ligature clips prevented assessment of some ITA
and radial grafts. Some arterial grafts had a thread-like ap-
pearance because of new stenosis in the native vessel or
poor runoff; these were identified with difficulty, and
some might have been classed as occluded. Despite these
difficulties, MDCTA assessment was not biased because
the radiologic assessors were blinded to randomized alloca-
tion.
Two other RCTs have assessed HRQoL, reporting that
improvements in HRQoL up to 1 year were similar with
CABG–CPB and OPCAB.4,22 Three-year follow-up of the
BHACASs also found no difference.10 The findings reported
here are consistent with these reports. We assessed patency
to address particular mechanistic hypotheses about OPCAB
but maintain that HRQoL provides the most important evi-
dence about the relative effectiveness of CABG–CPB and
OPCAB (ie, the patient’s view).10 Symptoms of ischemia af-
ter surgical intervention must be presumed to arise from ste-
noses that have developed since the operation and are likely
to precede events attributable to coronary disease. Although
new stenoses can arise either in grafts or native vessels, any
difference in ‘‘average’’ symptoms between groups can be
confidently attributed to operation type when patients have
been randomized and there is little attrition. Also, HRQoL
instruments are completely noninvasive and yield continu-
ous scores rather than binary outcomes, resulting in greater
power for a given sample size.
In addition to concern about graft patency, surgeons who
use CABG–CPB might be worried by evidence that surgeons
perform fewer grafts with OPCAB compared with CABG–
CPB. However, the absolute difference reported by a system-
atic review of 22 RCTs was only 0.2 grafts fewer with
OPCAB.1 This magnitude of difference was also observed
in the BHACAS trials and clearly had no effect on any out-
come.
We observed a significant reduction in the odds of graft
occlusion in BHACAS 2 compared with BHACAS 1, de-
spite broader eligibility criteria. Although the interaction
of trial by operation type was not statistically significant,
we attribute this at least in part to the learning curve and evo-
lution of OPCAB in our center during the trials, in particular
the attention given to careful surgical technique with better
stabilization and hemodynamic control.23 Aspects of tech-
niques developed for OPCAB might also have led to im-
proved CABG–CPB technique.
CONCLUSIONS
Long-term health outcomes with OPCAB are similar to
those with CABG–CPB. We found no evidence of long-
term harm associated with OPCAB.
We thank the participants in the BHACASs, particularly for their
willingness to contribute information over such a long period of fol-
low-up.Cardiovascular Surgery c Volume 137, Number 2 301
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Discussion
Dr Soichiro Kitamura (Osaka, Japan). I thank the Association
for the privilege of discussing this fine article. I also thank Professor
Angelini for allowing me to read the manuscript before the presen-
tation. My compliments on a well—designed and well—conducted
clinical study demonstrating again that OPCAB can offer good
quality of surgical intervention in terms of 6 to 8 years’ graft pa-
tency, survival and survival free from MACEs, and patients’
HRQoL after surgical intervention in comparison with conven-
tional on—pump CABG.
This article is certainly the extension of a previously published
randomized clinical trial called the BHACAS 1 and 2 conducted
almost 10 years ago, and today, the chief researchers again demon-
strated that OPCAB, as compared with on-pump CABG, can yield
a similar level of long-term survival and quality of life based on
the similar long-term graft patency evaluated by using 16-array
MDCTA.
Your group reported in 2002 and 2004 that OPCAB provided
significant reduction in postoperative morbidity compared with
that seen after conventional on-pump CABG, such as a 25% reduc-
tion in postoperative atrial fibrillation, a 31% reduction in blood
transfusion, fewer chest infections, shorter intensive care unit
stay, and so on. Also, a midterm follow-up study showed that ran-
domized patients had a similar generic and disease-specific quality
of life. However, OPCAB remains in only 15% to 20% of total
practice in Western countries, you said.
On the contrary, in Japan surgeons have adopted this technique
for about 60% of patients undergoing isolated CABG, and in my
institution, the National Cardiovascular Center, 98% of isolated
CABG procedures have been performed using the OPCAB tech-
nique, probably because in Japan angiographic follow-up is rather
routine, which can allow surgeons and cardiologists to evaluate and
confirm their own results. Very interestingly, once surgeons are
trained and accustomed to do it, they are reluctant to go back to
on-pump CABG because they are more comfortable with this tech-
nique because of easy hemostasis and easy adjustment of the graft
length for complicated graft arrangement. I believe the basic reason
for this technology not being popularized well, regardless of less
use of resources and reduction of early postoperative morbidity,
is the surgeons’ attitude anesthesiologists’ attitude, or both and
the training system.
My first question is this: Why has reduction in postoperative
morbidity contributed very little to the wide application of this tech-
nique? You mentioned that this was probably because of the con-
cern about long-term graft patency and clinical results. What
would you think about the importance of a training system, change
of attitude, or both for OPCAB rather than evidence demonstrated
by a handful of surgeons who are used to doing it?
Dr Angelini. Thank you, Dr Kitamura, for your kind remarks
and your very appropriate question, which is not easy to answer.
I have visited Japan on many occasions, and I have always been
surprised by the skill and level with which you have adopted OP-
CAB surgery and also arterial revascularization, 2 techniques that
are very poorly used in the Western world.rgery c February 2009
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DI think we have plenty of evidence on the benefits of OPCAB
surgery. To say, as I heard this morning, that a reduction in blood
loss is not such important evidence is a very feeble excuse. I think
this is a technique that requires an institution’s commitment to it
and not just the surgeon and anesthetist but the whole team, and
you have to be prepared to go through a learning process, which
can be painful. Perhaps this is one of the reasons why surgeons
are not prepared to adopt OPCAB surgery.
Maybe there is another explanation. I was reading an editorial
written 5 or 6 years ago by Lawrence Bonchek, a very well-known,
now retired, American surgeon, who asked, ‘‘Is off-pump for ev-
erybody?’’ After all, not all of us can perform mitral valve repair,
extensive arterial revascularization, or aortic valve sparing. There-
fore perhaps we should see the off-pump procedure as a specialized
procedure and to think that everybody will be able to adopt it is per-
haps just not feasible.
Dr Kitamura. Well, if I am correct, you are planning to con-
duct a new randomized trial of OPCAB versus CABG–CPB in
patients with poor left ventricular function. Conversion from
OPCAB to on-pump CABG in a hasty situation has been re-
ported to result in high mortality. Urgent conversion occursThe Journal of Thoracic and Cmore often in patients with poor and large left ventricles. At
present, would you think OPCAB should be limited for the pa-
tients with a low probability of conversion until new evidence
comes out?
Dr Angelini. Thank you, again, for this question. We are indeed
going to carry out a large study supported by the Medical Research
Council in the United Kingdom. The plan is to enroll 5000 patients
(EuroSCORE>5). Therefore these will be patients with poor ven-
tricular function but also redo operations, patients with renal im-
pairment, lung dysfunction, and so forth.
As far as conversion is concerned, our experience was reported
about 2 years ago in the European Journal of Cardio-Thoracic Sur-
gery; for the period 1995 to 2005, we had an overall conversion of
1.1%, going from 5.2% in the 1995 to 1996 period to less than 0.4%
in the most recent years. I think in institutions in which OPCAB
surgery has been adopted, after a proper learning curve, the risk
of conversion is very small.
DrKitamura. I once again congratulate you and your associates
on this excellent clinical research, and I hope this evidence can sig-
nificantly contribute to the prevalence of the OPCAB technique.
Thank you very much.ardiovascular Surgery c Volume 137, Number 2 303
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FIGURE E1. Graphic representation of interaction of operation type by
trial. Error bars are 95% confidence intervals. For the purposes of the graph,
the reference stratum is as follows: distal segment, saphenous vein, and in-
ferior territory. BHACAS, Beating Heart Against Cardioplegic Arrest Stud-
ies; CABG–CPB, Coronary artery bypass grafting with cardiopulmonary
bypass; OPCAB, off-pump coronary artery bypass.303.e1 The Journal of Thoracic and Cardiovascular Surgery c February 2009
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FIGURE E2. Graphic representation of operation type by graft segment.
Error bars are 95% confidence intervals. For the purposes of the graph,
the reference stratum is as follows: Beating Heart Against Cardioplegic Ar-
rest Studies 2, saphenous vein, and inferior territory.CABG–CPB, Coronary
artery bypass grafting with cardiopulmonary bypass; OPCAB, off-pump
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DTABLE E1. Logistic regression of graft occlusion: Model details without interaction of operation type by trial
Regression term Odds ratio Robust standard error z P> jzj 95% Confidence interval
CABG–CPB 1.00
OPCAB 0.998989 0.3019464 0.00 .997 0.5524377–1.806501
BHACAS 1 1.00
BHACAS 2 0.488524 0.149528 2.34 .019 0.2681327–0.8900672
Proximal segment 1.00
Body segment 1.022302 0.0561426 0.40 .688 0.9179798–1.13848
Distal segment 1.105597 0.0476357 2.33 .020 1.016067–1.203017
ITA* 1.00
Radial artery 2.725595 2.131022 1.28 .200 0.5887685–12.61764
Saphenous vein 1.338772 0.5262213 0.74 .458 0.6196282–2.892559
Inferior 1.00
Anterior 1.856419 0.8938422 1.28 .199 0.7224922–4.770004
Lateral 1.573124 0.6195576 1.15 .250 0.7269872–3.404077
Logistic regression
Number of observations ¼ 1364
Wald c2 (8) ¼ 18.41
Probability>c2 ¼ 0.0184
Log pseudolikelihood ¼459.49033
Pseudo R2 ¼ 0.0362
(Standard error adjusted for 199 clusters in id)
CABG–CPB, Coronary artery bypass grafting with cardiopulmonary bypass; OPCAB, off-pump coronary artery bypass; BHACAS, Beating Heart Against Cardioplegic Arrest Stud-
ies; ITA, internal thoracic artery. *Nineteen free internal thoracic artery grafts, none of which were occluded, were pooled with pedicle internal thoracic artery grafts so that they
could be included in the model.303.e3 The Journal of Thoracic and Cardiovascular Surgery c February 2009
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DTABLE E2. Logistic regression of graft occlusion: Model details with interaction of operation type by trial
Regression term Odds ratio Robust standard error z P> jzj 95% Confidence interval
CABG–CPB 1.00
OPCAB 1.148089 0.4513583 0.35 .725 0.5312944–2.480938
BHACAS 1 1.00
BHACAS 2 0.5685687 0.247001 1.30 .194 0.2426604–1.332192
OPCAB 3 BHACAS 2 0.7233592 0.4255386 0.55 .582y 0.2283537–2.291394
Proximal segment 1.00
Body segment 1.019942 0.0562281 0.36 .720 0.9154825–1.136322
Distal segment 1.104232 0.0476268 2.30 .022 1.014722–1.201638
ITA* 1.00
Radial artery 2.696345 2.08055 1.29 .199 0.5942548–12.23428
Saphenous vein 1.341522 0.5267276 0.75 .454 0.6214223–2.896068
Inferior 1.00
Anterior 1.884035 0.9009327 1.32 .185 0.7379899–4.809808
Lateral 1.558439 0.6153068 1.12 .261 0.7188139–3.378807
Logistic regression
Number of observations ¼ 1364
Wald c2 (9) ¼ 18.87
Probability>c2 ¼ .0263
Log pseudolikelihood ¼459.07974
Pseudo R2 ¼ 0.0370
(Standard error adjusted for 199 clusters in id)
CABG–CPB, Coronary artery bypass grafting with cardiopulmonary bypass; OPCAB, off-pump coronary artery bypass; BHACAS, Beating Heart Against Cardioplegic Arrest Stud-
ies; ITA, internal thoracic artery. *Nineteen free internal thoracic artery grafts, none of which were occluded, were pooled with pedicle internal thoracic artery grafts so that they
could be included in the model. yThe highlighted P value refers to the interaction of interest (c2 ¼ 0.30, df ¼ 1, P ¼ .582).The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 2 303.e4
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DTABLE E3. Logistic regression of graft occlusion: Model details with interaction of operation type by graft segment
Regression term Odds ratio Robust standard error z P> jzj 95% Confidence interval
CABG–CPB 1.00
OPCAB 1.075826 0.3407526 0.23 .818 0.5782771–2.001465
BHACAS 1 1.00
BHACAS 2 0.4879398 0.1495132 2.34 .019 0.2676353–0.8895883
Proximal segment 1.00
Body segment 1.031752 0.0541339 0.60 .551 0.9309244–1.1435
Distal segment 1.218846 0.0928309 2.60 .009 1.04983–1.415073
OPCAB 3 body 0.9800255 0.1091933 0.18 .036y 0.7877665–1.219207
OPCAB 3 dist 0.8174873 0.0702114 2.35 0.6908345–0.9673597
ITA* 1.00
Radial artery 2.737529 2.138362 1.29 .197 0.5921897–12.65484
Saphenous vein 1.337091 0.5256787 0.74 .460 0.6187425–2.889427
Inferior 1.00
Anterior 1.861796 0.8972326 1.29 .197 0.723974–4.787858
Lateral 1.574507 0.6204827 1.15 .249 0.7272819–3.408683
Logistic regression
Number of observations ¼ 1364
Wald c2 (10) ¼ 21.19
Probability>c2 ¼ 0.0198
Log pseudolikelihood ¼459.35623
Pseudo R2 ¼ 0.0364
(Standard error adjusted for 199 clusters in id)
CABG–CPB, Coronary artery bypass grafting with cardiopulmonary bypass; OPCAB, off-pump coronary artery bypass; BHACAS, Beating Heart Against Cardioplegic Arrest Stud-
ies; ITA, internal thoracic artery. *Nineteen free internal thoracic artery grafts, none of which were occluded, were pooled with pedicle internal thoracic artery grafts so that they
could be included in the model. yThe highlighted P value refers to the overall interaction term (c2 ¼ 6.65, df ¼ 2, P ¼ .036).303.e5 The Journal of Thoracic and Cardiovascular Surgery c February 2009
